<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mitral valve prolapse: Overview of complications and their management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mitral valve prolapse: Overview of complications and their management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mitral valve prolapse: Overview of complications and their management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Avi Sabbag, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maurice Enriquez-Sarano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Essayagh, MD, FESC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation (MR; eg, 72 percent of cases of moderate to severe primary MR [<a href="#rid1">1</a>]) in resource-abundant countries [<a href="#rid2">2</a>].</p><p>MVP is commonly suspected based on auscultatory findings and then confirmed by echocardiography or identified on echocardiography performed for other reasons. Earlier uncertainties regarding MVP complications were clarified after criteria for diagnosis of MVP were corrected to account for the saddle shape of the mitral annulus [<a href="#rid3">3</a>], as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis"</a>.)</p><p>This topic provides an overview of complications of MVP and their management. MVP is a progressive valve lesion that has a genetic basis [<a href="#rid4">4,5</a>] but tends to be fully developed later in life. This progression of the MVP lesions and consequences, physiologic and clinical, are the main source of complications [<a href="#rid6">6,7</a>]. Complications in patients with MVP are dominated by MR and its hemodynamic consequences but also include infective endocarditis, atrial and ventricular arrhythmias, ischemic neurologic events, development of tricuspid regurgitation, heart failure, and, rarely, sudden cardiac death (SCD) [<a href="#rid8">8</a>]. Clinical manifestations, diagnosis, and natural history of MVP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8163.html" rel="external">"Pathophysiology and natural history of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/8162.html" rel="external">"Natural history of chronic mitral regurgitation caused by mitral valve prolapse and flail mitral leaflet"</a>.)</p><p class="headingAnchor" id="H236054307"><span class="h1">TIME COURSE</span><span class="headingEndMark"> — </span>The mode and presentation of MVP complications can be highly variable:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute presentation </strong>is usually the result of the development of heart failure, atrial arrhythmias with rapid ventricular response, ventricular arrhythmias with or without sudden cardiac arrest, bacterial endocarditis, stroke, or acute ruptured chordae with chest pain and shortness of breath.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute presentation</strong> is the most frequent, with the predominant symptom of shortness of breath and, less often, palpitations or syncope.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insidious complications</strong> occur in patients who remain asymptomatic but who develop complications that are identified during routine follow-up. These include progression of MVP severity (with or without ruptured chord), progression of MR, left ventricular (LV) remodeling/dysfunction, left atrial remodeling, and hemodynamic alterations. While these insidious complications are most prominent with severe MR, occurrence in patients with less than severe MR is possible.</p><p></p><p class="bulletIndent1">Careful monitoring is recommended to minimize the incidence of clinical complications and mortality, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management", section on 'Monitoring'</a>.)</p><p></p><p class="headingAnchor" id="H702903563"><span class="h1">MITRAL REGURGITATION</span><span class="headingEndMark"> — </span>Outcomes in patients with MVP are largely determined by the presence and severity of associated primary mitral regurgitation (MR) and its hemodynamic consequences, including development of heart failure [<a href="#rid9">9,10</a>]  (<a class="graphic graphic_table graphicRef95916" href="/z/d/graphic/95916.html" rel="external">table 1</a>). While MVP represents the most common cause of severe primary MR in resource-abundant countries [<a href="#rid1">1,11</a>], only a minority of patients with MVP ultimately develop symptomatic severe MR due to profound leaflet prolapse and/or chordal rupture. The majority of patients with MVP with no or trivial MR generally incur a low risk of complications in the following years, but MR warrants monitoring.</p><p>Routine follow-up is essential for all patients with MVP and MR, with more frequent monitoring for patients with greater MR (larger regurgitant orifice and regurgitant volume), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management", section on 'Monitoring'</a>.)</p><p>Management of primary MR (including MVP with MR) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management"</a> and  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a> and  <a class="medical medical_review" href="/z/d/html/140775.html" rel="external">"Chronic primary mitral regurgitation: Choice of intervention"</a>.)</p><p class="headingAnchor" id="H654105062"><span class="h1">HEART FAILURE</span><span class="headingEndMark"> — </span>In patients with MVP, symptoms and signs consistent with heart failure warrant comprehensive evaluation for cardiac and noncardiac (eg, respiratory) causes using clinical and imaging assessment.</p><p class="headingAnchor" id="H3114000289"><span class="h2">Causes of symptoms of heart failure</span><span class="headingEndMark"> — </span>Among patients with severe mitral regurgitation (MR), 50 to 60 percent will develop heart failure within 10 years if not treated with mitral valve intervention [<a href="#rid12">12-14</a>].</p><p>While the risk of heart failure in patients with MVP is mainly determined by the severity of MR complicating MVP [<a href="#rid8">8,12</a>], other factors may precipitate or exacerbate heart failure, including the presence of other complications of MR (atrial fibrillation [AF], LV dysfunction, pulmonary hypertension, functional tricuspid regurgitation, right ventricular dysfunction) [<a href="#rid15">15-18</a>] and the presence of concurrent conditions (eg, obstructive coronary disease, senile amyloidosis, hypertensive heart disease) [<a href="#rid19">19</a>].</p><p>Also, symptoms associated with heart failure, such as shortness of breath, are not specific and may be caused by noncardiac conditions such as pulmonary disease and anemia. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H1397319623"><span class="h2">Importance of mitral valve intervention</span><span class="headingEndMark"> — </span>If the cause of heart failure in a patients with MVP is determined to be severe MR or complications of MR (eg, AF), medical treatment (eg, diuretic therapy) is only temporizing in preparation for an intervention to correct the MR [<a href="#rid9">9,10</a>]. Even patients who display marked symptomatic improvement or become asymptomatic after an episode of heart failure incur a substantial risk of mortality with continued medical management without mitral valve intervention [<a href="#rid13">13</a>], so mitral intervention should not be delayed in these patients. Undertreatment of MR remains a considerable problem resulting in profound excess mortality [<a href="#rid1">1,20</a>], in part because symptom improvement with medical treatment may be misinterpreted as a sufficient response to avoid mitral intervention. (See  <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management", section on 'Treatment of heart failure'</a> and  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p>In patients who present with AF as the main precipitant of heart failure in the context of moderate or severe MR, the appropriate first course of action is not AF ablation but mitral valve intervention, which is associated with improved outcomes [<a href="#rid21">21</a>]. Indications for mitral valve intervention and choice of mitral valve intervention in patients with MR are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p class="headingAnchor" id="H4012696198"><span class="h1">ISCHEMIC NEUROLOGIC EVENTS</span></p><p class="headingAnchor" id="H2636047739"><span class="h2">Risk of ischemic neurologic events</span><span class="headingEndMark"> — </span>In patients with MVP, the risk of ischemic neurologic events appears to be associated with thickened myxomatous leaflets and performance of cardiac surgery [<a href="#rid22">22</a>] (particularly mitral surgery, even mitral valve repair [<a href="#rid23">23</a>]) and more strongly associated with the following known risk factors for embolism (irrespective of presence of MVP): occurrence of AF and older age.</p><p>Thus, the concept of MR preventing thromboembolic events is not supported by the evidence and, indeed, patients with severe MR who are at high risk for AF and mitral surgery are at increased risk for ischemic neurologic events [<a href="#rid22">22</a>].</p><p>The relationship between MVP and risk of ischemic neurologic events (stroke and transient ischemic attack) has long been debated [<a href="#rid4">4</a>]. While some studies identified an association between MVP and risk of ischemic neurologic events, other studies have not. The concept that MVP may be a cause for ischemic neurologic events in young patients stemmed from rare observations of thrombi on the surface of mitral leaflets in patients with MVP [<a href="#rid24">24</a>] and a case control study of young patients with strokes that suggested an excess prevalence of MVP with strokes in this context [<a href="#rid25">25</a>].<strong> </strong>However, uncertainty remained because the diagnosis of MVP in the original case-control study [<a href="#rid25">25</a>] was based on outdated invalid criteria [<a href="#rid26">26</a>].</p><p>A subsequent case-control study was performed based on the correct diagnostic criteria for MVP, comparing 213 patients ≤45 years old with ischemic stroke or transient ischemic attacks with 263 control subjects. The prevalence of MVP was similar in the two groups (1.9 and 2.7 percent; odds ratio adjusted for age and sex 0.59, 95% CI 0.12-2.50) [<a href="#rid27">27</a>]. However, this study did not exclude a potential link between MVP and ischemic neurologic events over patients' lifetimes.</p><p>The risk of ischemic neurologic events (stroke or transient ischemic attack) was examined in a study of 777 patients with MVP (mean age 49 years) who were followed for a mean of 5.5 years [<a href="#rid22">22</a>]. Ischemic neurologic events occurred in 30 patients (4 percent). This event rate was significantly increased compared with the expected rate of neurologic events in the community adjusted for age, sex, and rhythm (relative risk [RR] 2.2, 95% CI 1.5-3.2). The estimated 10-year risk of an ischemic neurologic event under medical management was significantly increased for patients ≥50 years of age (13 percent), for those who developed AF (49 percent), and for those with thickened mitral valve leaflets (6 percent). Independent determinants of ischemic neurologic events were older age (RR 1.08 per year, 95% CI 1.04-1.11), mitral thickening (RR 3.2, 95% CI 1.4-7.4), AF during follow-up (RR 4.3, 95% CI 1.9-10.0), and need for cardiac surgery (RR 2.5, 95% CI 1.1-5.8). Older age and mitral valve thickening remained independent determinants of ischemic neurologic events when analysis was restricted to medical management. The risk of ischemic neurologic events was not increased in patients with MVP without leaflet thickening treated only with medical management but was increased in patients who had undergone mitral surgery.</p><p class="headingAnchor" id="H3583310461"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>For patients with MVP without history of thromboembolic events, AF, or mitral surgery, routine antithrombotic therapy is <strong>not</strong> required.</p><p>Standard recommendations for antithrombotic therapy apply to patients with MVP who have a concurrent indication for antithrombotic therapy such as transient ischemic attack, ischemic stroke, systemic embolism, or AF. General recommendations for antithrombotic therapy for AF and stroke are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1119.html" rel="external">"Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack"</a>.)</p><p>Recommendations for antithrombotic therapy after mitral valve repair or mitral valve replacement are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair"</a> and  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p class="headingAnchor" id="H102471012"><span class="h1">ATRIAL COMPLICATIONS OF MVP</span></p><p class="headingAnchor" id="H3002996353"><span class="h2">Atrial dilation</span><span class="headingEndMark"> — </span>The extent of atrial dilation in patients with MVP and mitral regurgitation (MR) is associated with severity of MR (due to the effects of the regurgitant volume), age, and diastolic dysfunction [<a href="#rid28">28</a>]. However, there is marked individual variation in the degree of left atrial (LA) dilation. Atrial dilation plays an important physiologic role in compensating for the MR associated with MVP and yields reduced (and, in some cases, normalization of) LA pressure even with severe MR [<a href="#rid29">29</a>], frequently with a prolonged asymptomatic phase.</p><p>Patients with marked LA dilation are at higher risk of developing subsequent AF [<a href="#rid30">30</a>] and are also at risk of excess mortality [<a href="#rid28">28,31</a>]. Patients with LA dilation identified by LA volume index (LAVI) ≥40 mL/m<sup>2</sup> are at moderate risk for AF and excess mortality. Those with LAVI ≥60 mL/m<sup>2 </sup>are at high risk for these complications [<a href="#rid28">28,31</a>].</p><p class="headingAnchor" id="H1660960351"><span class="h2">Risk of atrial fibrillation</span><span class="headingEndMark"> — </span>The risk of AF in patients with MVP is related to severity of MR, age, and atrial size [<a href="#rid32">32,33</a>]. In a study of 246 patients with MVP with MR undergoing mitral valve surgery, the frequency of chronic AF was 15 percent, and paroxysmal AF occurred in another 13 percent [<a href="#rid32">32</a>]. In another study of 89 patients with moderate to severe MR and MVP (without flail leaflet) and 360 patients with flail mitral leaflets, rates of AF were similar in the two groups (41 versus 44 percent at nine years of follow-up) [<a href="#rid33">33</a>]. The incidence of AF in patients diagnosed with severe MR in sinus rhythm has been estimated between 2.2 [<a href="#rid13">13</a>], 5.0 [<a href="#rid33">33</a>], and 5.4 percent [<a href="#rid14">14</a>] per year after the diagnosis of MVP. However, AF rates were much lower in patients younger than 65 than in patients older than 65 (26 versus 65 percent at 10 years) [<a href="#rid34">34</a>].</p><p>Among patients with MVP and MR, the occurrence of AF is associated with excess risk of heart failure and mortality [<a href="#rid33">33</a>]. This risk was illustrated by a study of 2425 patients with MVP, flail leaflet, and MR (severe in 94 percent) [<a href="#rid21">21</a>]. Presence of paroxysmal or persistent AF was associated with excess mortality (10-year survival in sinus rhythm, paroxysmal AF, and persistent AF was 74, 59, and 46 percent, respectively) [<a href="#rid21">21</a>]. This difference in survival rates persisted for 20 years independently of other baseline characteristics. Early mitral valve surgery (88 percent mitral valve repair) was associated with a marked survival benefit compared with medical management (adjusted hazard ratio 0.26, 95% CI 0.23-0.30) although survival for patients with AF was still lower than for patients with sinus rhythm (10-year postsurgical survival in sinus rhythm, paroxysmal AF, and persistent AF was 82, 70, and 57 percent, respectively).</p><p class="headingAnchor" id="H4007454972"><span class="h2">Management of atrial fibrillation</span><span class="headingEndMark"> — </span>In patients with MVP and severe MR, the above-described association between AF and mortality, with improved survival associated with mitral valve surgery [<a href="#rid21">21</a>], supports including the presence of AF (even paroxysmal) as a factor favoring prompt mitral surgery, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p>General recommendations for management of AF including treatment for rhythm and/or ventricular rate and indications for anticoagulation also apply to patients with MVP and AF, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a> and  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p class="headingAnchor" id="H1727106590"><span class="h1">VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH</span></p><p class="headingAnchor" id="H2869622397"><span class="h2">Clinical context</span><span class="headingEndMark"> — </span>The evidence linking MVP to the occurrence of SCD is sparse and relatively weak. The concept that MVP may lead to otherwise unexplained SCD has been based on case reports [<a href="#rid35">35-37</a>] or small case series [<a href="#rid38">38,39</a>] that are not adequate to establish causality. Limited evidence suggests that SCD in patients with MVP is usually due to ventricular fibrillation [<a href="#rid36">36,40</a>].</p><p>Consensus documents [<a href="#rid41">41,42</a>] have described two contexts in which the occurrence of SCD among patients with MVP may be observed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCD in MVP patients with severe mitral regurgitation </strong>– In such patients, the occurrence of SCD is thought to be related to volume overload. The argument in favor of this hypothesis is that among patients with MVP with severe mitral regurgitation (MR), SCD occurs at a rate higher under medical management than in an age-matched general population, and the rate of SCD after surgical correction of MR is lower, closer to that of the general population [<a href="#rid40">40</a>]. Furthermore, in patients with MVP and asymptomatic severe MR, the fact that the overall mortality rate after surgical correction is similar to that of general population strongly suggests that correction of MR yields normalization of the SCD rate [<a href="#rid43">43</a>]. Overall, the rate of SCD under medical management of severe MR is 1.8 percent per year but is markedly higher in patients with symptoms of heart failure or LV dysfunction [<a href="#rid40">40</a>]. In patients without risk factors, the rate of SCD is 0.8 percent per year under medical management, approximately double the rate of that in the general population [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCD in MVP independent of MR</strong> – Some data suggest that a small subset of patients with MVP have an arrhythmic MVP syndrome, with arrhythmic risk independent of MR severity [<a href="#rid41">41,44</a>]. This proposed syndrome is characterized by severe myxomatous disease with mitral annular disjunction (MAD), nonsustained ventricular tachycardia (NSVT), and risk of SCD. MAD is characterized by systolic separation of the mitral annulus supporting the posterior leaflet from the ventricular myocardium. However, the clinical significance of MAD has been debated, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis", section on 'Mitral annular disjunction'</a>.)</p><p></p><p class="bulletIndent1">A case series describing 10 cases of "malignant" MVP with bileaflet MVP and cardiac arrest without other explanation for SCD reignited the interest in defining this syndrome [<a href="#rid38">38</a>]. An international cohort of SCD with MVP as the sole possible explanation identified a relatively uniform (nonrandom) MVP phenotype with MAD [<a href="#rid45">45</a>]. In a cohort of 595 patients with MVP, severe NSVT was identified in 9 percent of patients by Holter monitoring [<a href="#rid44">44</a>]. While the subsequent rates of SCD could not be defined, the independent association of severe ventricular arrhythmias with excess subsequent mortality strongly supported a link between MVP and SCD. Furthermore, the cohort verified that severe arrhythmias were associated with a phenotype of MVP including MAD and severe myxomatous disease. Cardiovascular magnetic resonance (CMR) confirmed a link between MAD and ventricular arrhythmias. [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">The incidence of SCD in patients with MVP without significant MR remains uncertain, and a causal relationship has not been established. Autopsy studies that attempted to define the prevalence of MVP among patients that had suffered SCD and had pathologic verification of the absence of other causes found highly variable prevalence rates of MVP that, overall, were not different from that of MVP in the general population [<a href="#rid47">47-49</a>]. In population-based [<a href="#rid41">41</a>] and referral center [<a href="#rid50">50</a>] cohorts of patients with MVP with various degrees of MR, life expectancy was generally normal for patients with no or mild MR, ruling out a large contingent affected by SCD.</p><p></p><p class="headingAnchor" id="H4058190342"><span class="h2">Pathophysiologic mechanisms</span><span class="headingEndMark"> — </span>Several pathophysiologic mechanisms for arrhythmogenesis have been proposed; the arrhythmic substrate is likely replacement fibrosis that is presumed to result from chronic traction on the papillary muscles and perimitral myocardium by the extensive movement of the prolapsing leaflets and/or the abnormal mitral annulus [<a href="#rid51">51</a>]. Furthermore, increased stretch of myocyte is known to increase the likelihood of ventricular ectopy by prompting afterdepolarization-induced triggered activity, providing the necessary trigger for arrhythmia [<a href="#rid51">51-54</a>]. An additional potential trigger is the mechanical contact of the prolapsing leaflets slamming on the myocardium [<a href="#rid55">55</a>]. Lastly, the Purkinje tissue has been demonstrated to be a main source of ectopy capable of triggering malignant arrhythmia in patients with MVP [<a href="#rid56">56</a>].</p><p>On the other hand, both SCD and ventricular tachycardia (VT) can occur in patients without apparent structural heart disease, and excluding such cases may be complex. Specifically, it is difficult to rule out the presence of concurrent mild/early presentation of genetic diseases such as lamin A/C [<a href="#rid57">57</a>], filamin C [<a href="#rid58">58</a>], or long QT syndrome [<a href="#rid59">59</a>] in patients with MVP. (See  <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">"Approach to sudden cardiac arrest in the absence of apparent structural heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a>.)</p><p class="headingAnchor" id="H1511180290"><span class="h2">Clinical rhythm monitoring</span><span class="headingEndMark"> — </span>The role of implantable loop recording (ILR) in patients with MVP is poorly defined, but it is advised in patients with syncope without VT on standard 24 hours ambulatory (Holter) monitoring or for patients with MVP, palpitations, and nondiagnostic Holter monitoring [<a href="#rid41">41</a>].</p><p>Studies report high prevalences of atrial arrhythmias (eg, 48 percent) and ventricular arrhythmias (eg, 30 to 43 percent) in patients with MVP [<a href="#rid44">44,60-62</a>]. Severe ventricular arrhythmias (NSVT with rate ≥180 beats per minute [bpm]) has been reported in approximately 9 percent [<a href="#rid44">44</a>]. Most studies have been performed in adults; in children with MVP, ventricular arrhythmias are rare at diagnosis but tend to develop more frequently during follow-up [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H1783686370"><span class="h2">Risk stratification for SCD and ventricular arrhythmias</span><span class="headingEndMark"> — </span>The following approach for assessing risk of arrhythmia and SCD is suggested for individuals with MVP, although data to support this approach are limited [<a href="#rid41">41</a>]. It involves two steps; first, analyzing the MVP phenotype to assess the risk of arrhythmia and thereby the intensity of rhythm monitoring and, second, diagnosing the ventricular arrhythmias, symptomatic or not, that may create a high risk of SCD for patients.</p><p class="headingAnchor" id="H2432697113"><span class="h3">Clinical features associated with ventricular arrhythmias or SCD</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unexplained syncope</strong> is a symptom often preceding SCD in patients with MVP [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> <strong>MR</strong> – Patients with at least moderate to severe MR, irrespective of the MVP characteristics, are at heightened risk of SCD, particularly if symptomatic or associated with LV dysfunction [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVP characteristics</strong> –<strong> </strong>Patients with severe myxomatous leaflet remodeling are considered at increased risk of ventricular arrhythmias [<a href="#rid44">44,45</a>]. Bileaflet prolapse is often associated with severe myxomatous disease, but isolated bileaflet prolapse is not a harbinger of SCD [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitral annular disjunction</strong> – Patients with MAD associated with MVP are considered at heightened risk of ventricular arrhythmia, although the clinical significance of MAD remains controversial [<a href="#rid45">45,46,65,66</a>]. The incidence of ventricular arrhythmias in patients with MAD is modest, and MAD, in and of itself, is not linked to excess mortality [<a href="#rid66">66</a>]. MAD has also been described in patients who are not diagnosed with MVP and is also associated with ventricular arrhythmias in this context [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG findings</strong> – Electrocardiographic (ECG) repolarization abnormalities are often located in the inferior territory and are more frequent in patients who present with arrhythmias [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">The presence of frequent and/or polymorphic ventricular extrasystole originating in the perimitral region is often observed on routine ECG in patients who later present with more severe ventricular arrhythmias or SCD [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial fibrosis by CMR</strong> – CMR enables identification of myocardial fibrosis by late gadolinium enhancement (LGE). LGE detected around the mitral apparatus, annulus, posterior wall, and papillary muscles is considered as a mechanistic factor yielding ventricular arrhythmias [<a href="#rid16">16,67</a>].</p><p></p><p class="bulletIndent1">CMR is indicated in patients with suboptimal echocardiographic assessment of MVP, MR, and MAD, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis", section on 'Cardiovascular magnetic resonance'</a>.)</p><p></p><p class="bulletIndent1">The following additional indications for CMR have been proposed but are not established [<a href="#rid41">41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MVP who have survived cardiac arrest or have experienced sustained VT prior to implantable cardioverter-defibrillator (ICD) implantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MVP and unexplained syncope and/or nonsustained VT.</p><p></p><p class="headingAnchor" id="H2573079087"><span class="h3">Serial monitoring</span><span class="headingEndMark"> — </span>Serial monitoring suggested for patients with MVP and significant MR includes echocardiography and ambulatory ECG monitoring [<a href="#rid41">41</a>]. The role of ILR in patients with MVP is not well-defined.</p><p>The combination of the above factors is essential in defining the intensity of monitoring for arrhythmias. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Ambulatory monitoring is not required for patients with MVP, mild MR, and no symptoms or infrequent palpitations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with MVP and palpitations should have ambulatory monitoring for diagnosis of the cause and frequency of arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/6835.html" rel="external">"Evaluation of palpitations in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with unexplained syncope, abnormal repolarization, MVP with severe myxomatous disease, polymorphic extrasystole, and myocardial fibrosis should have prolonged ambulatory monitoring and, possibly, ILR until ventricular arrhythmias are identified or effectively ruled out.</p><p></p><p class="headingAnchor" id="H1429388338"><span class="h3">Categorizing ventricular arrhythmias</span><span class="headingEndMark"> — </span>In patients with MVP, ventricular arrhythmias unexplained by other cause are thought to be related to the presence of MVP, although the possibility of a genetically linked separate etiology cannot be excluded [<a href="#rid44">44</a>].</p><p>Arrhythmias may be stratified as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>None to minimal</strong> – Premature ventricular complexes/contractions (PVCs; also referred to as premature ventricular beats or premature ventricular depolarizations) &lt;5 percent of heart beats by Holter monitoring and absence of more serious arrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – Monomorphic isolated PVCs that are ≥5 percent of heart beats.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate</strong> –<strong> </strong>Polymorphic isolated PVCs or<strong> </strong>monomorphic NSVT of maximum rate &lt;180 bpm and monomorphic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> – Sustained VT or NSVT at ≥180 bpm and/or polymorphic. MVP with severe ventricular arrhythmia is associated with excess subsequent mortality [<a href="#rid44">44</a>]. Management is based on the severity of the arrhythmia and whether there is associated severe MR. This syndrome was recognized by a consensus panel gathered by the European Heart Rhythm Association (EHRA) and endorsed by several cardiology societies [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate threat</strong> – Hemodynamically complicated sustained VT or ventricular fibrillation resulting in sudden cardiac arrest (SCA).</p><p></p><p class="headingAnchor" id="H308372497"><span class="h3">Role of electrophysiologic study</span><span class="headingEndMark"> — </span>A role for electrophysiologic study in patients with MVP has not been defined [<a href="#rid41">41</a>]. Data regarding the value of programmed stimulation in patients with MVP are very sparse [<a href="#rid68">68</a>], and the consensus is that the clinical value of complex arrhythmias induced under these circumstances is subject to caution and rarely yields indications for ICD implantation [<a href="#rid41">41</a>].</p><p>Conversely, after ICD implantation for SCA and recurrent ventricular fibrillation, electrophysiologic determination of the site and mechanism of recurrent arrhythmias is useful for radiofrequency ablation [<a href="#rid41">41</a>]. Similarly, programmed ventricular stimulation in a high proportion of patients with frequent PVCs/VT and MAD enables identification of the mitral annular origin of arrhythmias and successful ablation of the responsible foci [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies", section on 'Programmed electrical stimulation'</a>.)</p><p class="headingAnchor" id="H2139983262"><span class="h2">Management of ventricular arrhythmias</span><span class="headingEndMark"> — </span>The therapy indicated is based on the severity of the arrhythmia and its association to severe MR. The following approach is in broad agreement with the EHRA expert consensus statement, which addresses the following categories [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVP with SCA or sustained VT</strong> –<strong> </strong>Survivors of SCA or sustained VT without a clearly reversible cause are considered to be at high risk for subsequent SCA. Indication for ICD with secondary consideration for VT ablation in case of recurrent appropriate discharge of the device. Standard recommendations for ICD implantation apply to patients with MVP and either SCA or sustained VT, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1">Depending on the severity of MR, mitral valve repair may be indicated before or after ICD implantation. For patients with high-risk VT and severe primary MR, mitral valve intervention may reduce the risk of ventricular arrhythmias, but the efficacy of this approach has not been established. Indications for mitral intervention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVP with heart failure and LV ejection fraction ≤35 percent</strong> – The standard indication for ICD for primary prevention of SCD is applicable to patients with MVP. However, the indication is for patients with symptomatic heart failure with LV ejection fraction (LVEF) ≤35 percent despite three months of optimal medical therapy, as discussed separately, and such a low LVEF is rare among patients with MVP. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe MR and NSVT</strong> – In patients with NSVT and severe MR treated with mitral valve intervention, the role of adjunctive ICD implantation or VT ablation has not been defined [<a href="#rid41">41</a>]. General indications for intervention in patients with MVP and MR are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a> and  <a class="medical medical_review" href="/z/d/html/8170.html" rel="external">"Acute mitral regurgitation in adults"</a>.)</p><p></p><p class="bulletIndent1">In observational studies, surgical correction of MR in patients with MVP was associated with reduced all-cause mortality in patients with MVP and MR [<a href="#rid12">12</a>] and reduced incidence of SCD in patients with flail mitral leaflet [<a href="#rid40">40</a>]. However, the efficacy of mitral valve repair or replacement in reducing the risk of SCD in patients with severe MR and ventricular arrhythmias has not been established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PVC-induced cardiomyopathy </strong>– PVC-induced cardiomyopathy is presumed in a patient with high burden of PVCs (ie, &gt;15 percent) and LVEF &lt;50 percent. Management, including beta blockers, ablation, and antiarrhythmic therapy, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122361.html" rel="external">"Premature ventricular complexes: Treatment and prognosis", section on 'Premature ventricular complex cardiomyopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVP with mild or moderate arrhythmia</strong> – Frequent Holter monitoring or ILR is suggested depending on the baseline arrhythmias and phenotype of the MVP. (See  <a class="medical medical_review" href="/z/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVP with no arrhythmia</strong> – If symptoms such as unexplained presyncope or syncope develop, evaluation commonly includes ambulatory ECG (Holter) monitoring, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/126940.html" rel="external">"Syncope in adults: Risk assessment and additional diagnostic evaluation"</a>.)</p><p></p><p>While the EHRA expert consensus statement suggested periodic Holter monitoring for individuals with MVP and no symptoms [<a href="#rid41">41</a>], the clinical utility and frequency of such monitoring has not been defined.</p><p class="headingAnchor" id="H2966450412"><span class="h1">INFECTIVE ENDOCARDITIS</span><span class="headingEndMark"> — </span>Despite the risk of infective endocarditis (IE) in patients with MVP and mitral regurgitation (MR), routine antibiotic prophylaxis is not indicated for these patients (in the absence of history of IE or prior valve repair or replacement) [<a href="#rid9">9,10,70</a>]. Preventive measures for patients with MVP include maintenance of oral hygiene and timely treatment of any infections with pathogens that cause endocarditis. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p>This approach is justified by the rarity (37 percent) of cases of IE on MVP in which the point of entry can be defined [<a href="#rid71">71</a>] and the low incidence of IE in patients with MVP. Indeed, while the risk of IE is higher with MVP than with a normal mitral valve, the absolute risk of infection is low. A population-based study of 896 adults with MVP found that the 15-year risk of IE was 1.1 percent (86.6 cases per 100,000 person-years) [<a href="#rid72">72</a>]. The age- and sex-adjusted relative risk of IE in patients with MVP was 8.1 (95% CI 3.6-18.0) compared with the general population. The incidence of IE was higher in patients with moderate or greater MR (289.5 cases per 100,000 years) compared with patients with less than moderate MR (63.3 cases per 100,000 person-years). No IE cases were identified in patients without previously diagnosed MR. Although data were limited, the risk of IE was higher in patients with flail mitral leaflet (715.5 cases per 100,000 person-years).</p><p class="headingAnchor" id="H536006377"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H21043120"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of MVP</strong> – Complications in patients with mitral valve prolapse (MVP) include mitral regurgitation (MR), heart failure, left atrial (LA) dilation with atrial fibrillation (AF), infective endocarditis (IE), ventricular arrhythmias, and, rarely, sudden cardiac death (SCD). The time course of complications is variable. (See <a class="local">'Introduction'</a> above and <a class="local">'Time course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitral regurgitation</strong> – Outcomes in patients with MVP are largely determined by the presence and severity of MR. Monitoring and management of MR are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management"</a> and  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart Failure </strong>– Heart failure in patients with MVP is primarily related to the severity of MR but is also influenced by other complications (eg, left ventricular [LV] dysfunction or AF). In patients with heart failure caused by MR, medical treatment is only temporizing in preparation for mitral valve intervention. (See <a class="local">'Importance of mitral valve intervention'</a> above and  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic neurologic events</strong> – Ischemic neurologic events complicating MVP are mostly due to concurrent conditions, such as AF, and mitral surgery. Ischemic neurologic events are rare in patients with uncomplicated MVP. For patients with MVP without history of thromboembolic events, AF, or mitral surgery, routine antithrombotic therapy is <strong>not</strong> required. (See <a class="local">'Ischemic neurologic events'</a> above.)</p><p></p><p class="bulletIndent1">Antithrombotic therapy after mitral valve surgery (repair or replacement) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair"</a> and  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LA dilation and AF </strong>– In patients with MVP and MR, marked LA dilation is associated with subsequent excess mortality and risk of AF. The occurrence of AF is associated with adverse outcomes and warrants prompt consideration of mitral intervention. (See <a class="local">'Risk of atrial fibrillation'</a> above and <a class="local">'Management of atrial fibrillation'</a> above and  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification for SCD</strong> – The risk of sudden cardiac arrest or ventricular arrhythmia is increased in patients with MVP with one or more high risk features: unexplained syncope, at least moderate to severe MR, repolarization abnormalities or ventricular arrhythmias on ECG, severe myxomatous mitral leaflet degeneration, mitral annular disjunction, or late gadolinium enhancement (LGE) of the papillary muscles or periannular area on cardiovascular magnetic resonance (CMR) imaging. The role of rhythm monitoring is determined by the presence of risk factors. (See <a class="local">'Risk stratification for SCD and ventricular arrhythmias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of ventricular arrhythmias</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SCA or sustained VT</strong> – For patients with MVP with prior sudden cardiac arrest or sustained ventricular tachycardia (VT), standard recommendations for implantable cardioverter-defibrillator (ICD) implantation apply, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent2">Depending on the severity of MR, mitral valve repair may be indicated before or after ICD implantation. For patients with high-risk VT and severe primary MR, mitral valve intervention may reduce the risk of ventricular arrhythmias, but the efficacy of this approach has not been established. Indications for mitral intervention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary prevention of SCD</strong> – The standard indication for ICD for primary prevention of SCD applies to patients with MVP. However, the indication is for patients with symptomatic heart failure with LV ejection fraction (LVEF) ≤35 percent despite three months of optimal medical therapy, as discussed separately, and such a low LVEF is rare among patients with MVP. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infective endocarditis</strong> – Although patients with MVP and MR are at risk for developing IE, routine antibiotic prophylaxis is not indicated for these patients (in the absence of history of IE or prior valve repair or replacement). (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p></p><p class="headingAnchor" id="H2712449192"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Sorin Pislaru, MD, and Matthew Sorrentino, MD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges William H Gaasch, MD (deceased), who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur Heart J 2019; 40:2194.</a></li><li><a class="nounderline abstract_t">Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.</a></li><li><a class="nounderline abstract_t">Levine RA, Stathogiannis E, Newell JB, et al. Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J Am Coll Cardiol 1988; 11:1010.</a></li><li><a class="nounderline abstract_t">Morningstar JE, Nieman A, Wang C, et al. Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition. J Am Heart Assoc 2021; 10:e020919.</a></li><li><a class="nounderline abstract_t">Roselli C, Yu M, Nauffal V, et al. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur Heart J 2022; 43:1668.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral regurgitation: a prospective Doppler echocardiographic study. J Am Coll Cardiol 1999; 34:1137.</a></li><li><a class="nounderline abstract_t">Delling FN, Rong J, Larson MG, et al. Evolution of Mitral Valve Prolapse: Insights From the Framingham Heart Study. Circulation 2016; 133:1688.</a></li><li><a class="nounderline abstract_t">Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561.</a></li><li><a class="nounderline abstract_t">de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. J Card Surg 2011; 26:385.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.</a></li><li><a class="nounderline abstract_t">Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 1996; 335:1417.</a></li><li><a class="nounderline abstract_t">Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging 2008; 1:133.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Congestive heart failure after surgical correction of mitral regurgitation. A long-term study. Circulation 1995; 92:2496.</a></li><li><a class="nounderline abstract_t">Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, et al. Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia. Circulation 2021; 143:1763.</a></li><li><a class="nounderline abstract_t">Kernis SJ, Nkomo VT, Messika-Zeitoun D, et al. Atrial fibrillation after surgical correction of mitral regurgitation in sinus rhythm: incidence, outcome, and determinants. Circulation 2004; 110:2320.</a></li><li><a class="nounderline abstract_t">Essayagh B, Antoine C, Benfari G, et al. Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival. Eur Heart J 2020; 41:1918.</a></li><li><a class="nounderline abstract_t">Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Excess mortality due to coronary artery disease after valve surgery. Secular trends in valvular regurgitation and effect of internal mammary artery bypass. Circulation 1998; 98:II108.</a></li><li><a class="nounderline abstract_t">Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet 2018; 391:960.</a></li><li><a class="nounderline abstract_t">Grigioni F, Benfari G, Vanoverschelde JL, et al. Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation. J Am Coll Cardiol 2019; 73:264.</a></li><li><a class="nounderline abstract_t">Avierinos JF, Brown RD, Foley DA, et al. Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors. Stroke 2003; 34:1339.</a></li><li><a class="nounderline abstract_t">Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008; 51:1203.</a></li><li><a class="nounderline abstract_t">Ricci D, Gori T, Donati G, et al. Embolizing mobile thrombus associated with prolapse and mixoid degeneration of the mitral valve. Int J Cardiol 2000; 74:239.</a></li><li><a class="nounderline abstract_t">Barnett HJ, Boughner DR, Taylor DW, et al. Further evidence relating mitral-valve prolapse to cerebral ischemic events. N Engl J Med 1980; 302:139.</a></li><li><a class="nounderline abstract_t">Levine RA, Handschumacher MD, Sanfilippo AJ, et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 1989; 80:589.</a></li><li><a class="nounderline abstract_t">Gilon D, Buonanno FS, Joffe MM, et al. Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 1999; 341:8.</a></li><li><a class="nounderline abstract_t">Essayagh B, Antoine C, Benfari G, et al. Prognostic Implications of Left Atrial Enlargement in Degenerative Mitral Regurgitation. J Am Coll Cardiol 2019; 74:858.</a></li><li><a class="nounderline abstract_t">Sims JR, Reeder GS, Guerrero M, et al. Characteristics and outcomes of patients with normal left atrial pressure undergoing transcatheter mitral valve repair. Heart 2020; 106:898.</a></li><li><a class="nounderline abstract_t">Messika-Zeitoun D, Bellamy M, Avierinos JF, et al. Left atrial remodelling in mitral regurgitation--methodologic approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-echocardiographic and electron beam-computed tomographic study. Eur Heart J 2007; 28:1773.</a></li><li><a class="nounderline abstract_t">Le Tourneau T, Messika-Zeitoun D, Russo A, et al. Impact of left atrial volume on clinical outcome in organic mitral regurgitation. J Am Coll Cardiol 2010; 56:570.</a></li><li><a class="nounderline abstract_t">Berbarie RF, Roberts WC. Frequency of atrial fibrillation in patients having mitral valve repair or replacement for pure mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 2006; 97:1039.</a></li><li><a class="nounderline abstract_t">Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol 2002; 40:84.</a></li><li><a class="nounderline abstract_t">Avierinos JF, Tribouilloy C, Grigioni F, et al. Impact of ageing on presentation and outcome of mitral regurgitation due to flail leaflet: a multicentre international study. Eur Heart J 2013; 34:2600.</a></li><li><a class="nounderline abstract_t">Bharati S, Granston AS, Liebson PR, et al. The conduction system in mitral valve prolapse syndrome with sudden death. Am Heart J 1981; 101:667.</a></li><li><a class="nounderline abstract_t">Martini B, Basso C, Thiene G. Sudden death in mitral valve prolapse with Holter monitoring-documented ventricular fibrillation: evidence of coexisting arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 1995; 49:274.</a></li><li><a class="nounderline abstract_t">Chivulescu M, Aabel E, Dejgaard L, et al. Cardiac Arrest in a Patient With Arrhythmic Mitral Valve Prolapse Syndrome: Multiple Possible Etiologies. JACC Case Rep 2021; 3:1769.</a></li><li><a class="nounderline abstract_t">Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. J Am Coll Cardiol 2013; 62:222.</a></li><li><a class="nounderline abstract_t">Boudoulas H, Schaal SF, Stang JM, et al. Mitral valve prolapse: cardiac arrest with long-term survival. Int J Cardiol 1990; 26:37.</a></li><li><a class="nounderline abstract_t">Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 1999; 34:2078.</a></li><li><a class="nounderline abstract_t">Sabbag A, Essayagh B, Barrera JDR, et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society. Europace 2022; 24:1981.</a></li><li><a class="nounderline abstract_t">Delling FN, Noseworthy PA, Adams DH, et al. Research Opportunities in the Treatment of Mitral Valve Prolapse: JACC Expert Panel. J Am Coll Cardiol 2022; 80:2331.</a></li><li><a class="nounderline abstract_t">Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 1999; 99:400.</a></li><li><a class="nounderline abstract_t">Essayagh B, Sabbag A, Antoine C, et al. Presentation and Outcome of Arrhythmic Mitral Valve Prolapse. J Am Coll Cardiol 2020; 76:637.</a></li><li><a class="nounderline abstract_t">Hourdain J, Clavel MA, Deharo JC, et al. Common Phenotype in Patients With Mitral Valve Prolapse Who Experienced Sudden Cardiac Death. Circulation 2018; 138:1067.</a></li><li><a class="nounderline abstract_t">Essayagh B, Iacuzio L, Civaia F, et al. Usefulness of 3-Tesla Cardiac Magnetic Resonance to Detect Mitral Annular Disjunction in Patients With Mitral Valve Prolapse. Am J Cardiol 2019; 124:1725.</a></li><li><a class="nounderline abstract_t">Basso C, Perazzolo Marra M, Rizzo S, et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. Circulation 2015; 132:556.</a></li><li><a class="nounderline abstract_t">Han HC, Parsons SA, Teh AW, et al. Characteristic Histopathological Findings and Cardiac Arrest Rhythm in Isolated Mitral Valve Prolapse and Sudden Cardiac Death. J Am Heart Assoc 2020; 9:e015587.</a></li><li><a class="nounderline abstract_t">Delling FN, Aung S, Vittinghoff E, et al. Antemortem and Post-Mortem Characteristics of Lethal Mitral Valve Prolapse Among All Countywide Sudden Deaths. JACC Clin Electrophysiol 2021; 7:1025.</a></li><li><a class="nounderline abstract_t">Antoine C, Benfari G, Michelena HI, et al. Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice. Circulation 2018; 138:1317.</a></li><li><a class="nounderline abstract_t">Perazzolo Marra M, Basso C, De Lazzari M, et al. Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse. Circ Cardiovasc Imaging 2016; 9:e005030.</a></li><li><a class="nounderline abstract_t">Franz MR. Mechano-electrical feedback. Cardiovasc Res 2000; 45:263.</a></li><li><a class="nounderline abstract_t">Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback. Circulation 1990; 81:1094.</a></li><li><a class="nounderline abstract_t">Hansen DE, Cahill PD, DeCampli WM, et al. Valvular-ventricular interaction: importance of the mitral apparatus in canine left ventricular systolic performance. Circulation 1986; 73:1310.</a></li><li><a class="nounderline abstract_t">Noseworthy PA, Asirvatham SJ. The Knot That Binds Mitral Valve Prolapse and Sudden Cardiac Death. Circulation 2015; 132:551.</a></li><li><a class="nounderline abstract_t">Syed FF, Ackerman MJ, McLeod CJ, et al. Sites of Successful Ventricular Fibrillation Ablation in Bileaflet Mitral Valve Prolapse Syndrome. Circ Arrhythm Electrophysiol 2016; 9.</a></li><li><a class="nounderline abstract_t">Mahajan AM, Itan Y, Cerrone M, et al. Sudden Cardiac Arrest in a Patient With Mitral Valve Prolapse and LMNA and SCN5A Mutations. JACC Case Rep 2021; 3:242.</a></li><li><a class="nounderline abstract_t">Bains S, Tester DJ, Asirvatham SJ, et al. A Novel Truncating Variant in FLNC-Encoded Filamin C May Serve as a Proarrhythmic Genetic Substrate for Arrhythmogenic Bileaflet Mitral Valve Prolapse Syndrome. Mayo Clin Proc 2019; 94:906.</a></li><li><a class="nounderline abstract_t">Giudicessi JR, Rohatgi RK, Bos JM, Ackerman MJ. Prevalence and clinical phenotype of concomitant long QT syndrome and arrhythmogenic bileaflet mitral valve prolapse. Int J Cardiol 2019; 274:175.</a></li><li><a class="nounderline abstract_t">Zuppiroli A, Mori F, Favilli S, et al. Arrhythmias in mitral valve prolapse: relation to anterior mitral leaflet thickening, clinical variables, and color Doppler echocardiographic parameters. Am Heart J 1994; 128:919.</a></li><li><a class="nounderline abstract_t">Turker Y, Ozaydin M, Acar G, et al. Predictors of ventricular arrhythmias in patients with mitral valve prolapse. Int J Cardiovasc Imaging 2010; 26:139.</a></li><li><a class="nounderline abstract_t">Turker Y, Ozaydin M, Acar G, et al. Predictors of atrial arrhythmias in patients with mitral valve prolapse. Acta Cardiol 2009; 64:755.</a></li><li><a class="nounderline abstract_t">Bobkowski W, Siwińska A, Zachwieja J, et al. A prospective study to determine the significance of ventricular late potentials in children with mitral valvar prolapse. Cardiol Young 2002; 12:333.</a></li><li><a class="nounderline abstract_t">Nordhues BD, Siontis KC, Scott CG, et al. Bileaflet Mitral Valve Prolapse and Risk of Ventricular Dysrhythmias and Death. J Cardiovasc Electrophysiol 2016; 27:463.</a></li><li><a class="nounderline abstract_t">Dejgaard LA, Skjølsvik ET, Lie ØH, et al. The Mitral Annulus Disjunction Arrhythmic Syndrome. J Am Coll Cardiol 2018; 72:1600.</a></li><li><a class="nounderline abstract_t">Essayagh B, Sabbag A, Antoine C, et al. The Mitral Annular Disjunction of Mitral Valve Prolapse: Presentation and Outcome. JACC Cardiovasc Imaging 2021; 14:2073.</a></li><li><a class="nounderline abstract_t">Han Y, Peters DC, Salton CJ, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging 2008; 1:294.</a></li><li><a class="nounderline abstract_t">Rosenthal ME, Hamer A, Gang ES, et al. The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias. Am Heart J 1985; 110:970.</a></li><li><a class="nounderline abstract_t">Chakrabarti AK, Deshmukh A, Liang JJ, et al. Mitral Annular Substrate and Ventricular Arrhythmias in Arrhythmogenic Mitral Valve Prolapse With Mitral Annular Disjunction. JACC Clin Electrophysiol 2023; 9:1265.</a></li><li><a class="nounderline abstract_t">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</a></li><li><a class="nounderline abstract_t">Zegri-Reiriz I, de Alarcón A, Muñoz P, et al. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. J Am Coll Cardiol 2018; 71:2731.</a></li><li><a class="nounderline abstract_t">Katan O, Michelena HI, Avierinos JF, et al. Incidence and Predictors of Infective Endocarditis in Mitral Valve Prolapse: A Population-Based Study. Mayo Clin Proc 2016; 91:336.</a></li></ol></div><div id="topicVersionRevision">Topic 8169 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31121021" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10387935" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence and clinical outcome of mitral-valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281989" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35245370" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520803" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Progression of mitral regurgitation: a prospective Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006478" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolution of Mitral Valve Prolapse: Insights From the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221052" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Natural history of asymptomatic mitral valve prolapse in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453165" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2021 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793928" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745978" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Quantitative determinants of the outcome of asymptomatic mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8875918" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical outcome of mitral regurgitation due to flail leaflet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356418" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outcomes in mitral regurgitation due to flail leaflets a multicenter European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586350" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Congestive heart failure after surgical correction of mitral regurgitation. A long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33706538" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477410" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atrial fibrillation after surgical correction of mitral regurgitation in sinus rhythm: incidence, outcome, and determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32300779" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852890" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Excess mortality due to coronary artery disease after valve surgery. Secular trends in valvular regurgitation and effect of internal mammary artery bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536860" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcome and undertreatment of mitral regurgitation: a community cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30678755" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738894" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355659" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11203046" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Embolizing mobile thrombus associated with prolapse and mixoid degeneration of the mitral valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350439" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Further evidence relating mitral-valve prolapse to cerebral ischemic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2766511" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10387936" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lack of evidence of an association between mitral-valve prolapse and stroke in young patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31416529" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic Implications of Left Atrial Enlargement in Degenerative Mitral Regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980440" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characteristics and outcomes of patients with normal left atrial pressure undergoing transcatheter mitral valve repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562673" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Left atrial remodelling in mitral regurgitation--methodologic approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-echocardiographic and electron beam-computed tomographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688212" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of left atrial volume on clinical outcome in organic mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563912" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Frequency of atrial fibrillation in patients having mitral valve repair or replacement for pure mitral regurgitation secondary to mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12103260" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23853072" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of ageing on presentation and outcome of mitral regurgitation due to flail leaflet: a multicentre international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7223606" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The conduction system in mitral valve prolapse syndrome with sudden death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7649675" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sudden death in mitral valve prolapse with Holter monitoring-documented ventricular fibrillation: evidence of coexisting arrhythmogenic right ventricular cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34825207" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiac Arrest in a Patient With Arrhythmic Mitral Valve Prolapse Syndrome: Multiple Possible Etiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563135" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298517" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mitral valve prolapse: cardiac arrest with long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588227" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sudden death in mitral regurgitation due to flail leaflet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35951656" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36480975" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Research Opportunities in the Treatment of Mitral Valve Prolapse: JACC Expert Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918527" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32762897" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Presentation and Outcome of Arrhythmic Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354542" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Common Phenotype in Patients With Mitral Valve Prolapse Who Experienced Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606191" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Usefulness of 3-Tesla Cardiac Magnetic Resonance to Detect Mitral Annular Disjunction in Patients With Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160859" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32233752" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Characteristic Histopathological Findings and Cardiac Arrest Rhythm in Isolated Mitral Valve Prolapse and Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640349" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antemortem and Post-Mortem Characteristics of Lethal Mitral Valve Prolapse Among All Countywide Sudden Deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29853518" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516479" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728344" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mechano-electrical feedback.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689619" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3698258" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Valvular-ventricular interaction: importance of the mitral apparatus in canine left ventricular systolic performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160860" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Knot That Binds Mitral Valve Prolapse and Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27103091" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sites of Successful Ventricular Fibrillation Ablation in Bileaflet Mitral Valve Prolapse Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34317510" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sudden Cardiac Arrest in a Patient With Mitral Valve Prolapse and LMNA and SCN5A Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30935706" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Novel Truncating Variant in FLNC-Encoded Filamin C May Serve as a Proarrhythmic Genetic Substrate for Arrhythmogenic Bileaflet Mitral Valve Prolapse Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30219255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevalence and clinical phenotype of concomitant long QT syndrome and arrhythmogenic bileaflet mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942485" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Arrhythmias in mitral valve prolapse: relation to anterior mitral leaflet thickening, clinical variables, and color Doppler echocardiographic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847667" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Predictors of ventricular arrhythmias in patients with mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20128151" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Predictors of atrial arrhythmias in patients with mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12206555" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A prospective study to determine the significance of ventricular late potentials in children with mitral valvar prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749260" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bileaflet Mitral Valve Prolapse and Risk of Ventricular Dysrhythmias and Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30261961" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The Mitral Annulus Disjunction Arrhythmic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34147457" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The Mitral Annular Disjunction of Mitral Valve Prolapse: Presentation and Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356441" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular magnetic resonance characterization of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4061272" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37086231" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mitral Annular Substrate and Ventricular Arrhythmias in Arrhythmogenic Mitral Valve Prolapse With Mitral Annular Disjunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903346" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26856780" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Incidence and Predictors of Infective Endocarditis in Mitral Valve Prolapse: A Population-Based Study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
